疫苗ETF（159643）盘中涨超1.2%，医药生物呈结构性机会

Core Insights - The pharmaceutical and biotechnology industry is experiencing a peak in license-out transactions, with 103 deals totaling $92.03 billion in the first three quarters of 2025, representing a 77% increase compared to the total for 2024 [1] - Despite an 8.17% decline in the innovative drug index, external licensing remains a significant catalyst for industry growth, particularly in the dual antibody and ADC sectors, which have established a first-mover advantage [1] - Novo Nordisk and Eli Lilly announced plans to reduce the prices of GLP-1 products starting in 2026 to enhance accessibility and solidify their leading positions in the market [1] Industry Overview - The Vaccine ETF (159643) tracks the Vaccine Biotechnology Index (980015), which selects listed companies involved in bioproducts, life science tools, and services, focusing on vaccine research, production, and related services [1] - The constituent stocks of the index exhibit significant innovation and growth characteristics, reflecting the overall performance and technological development trends in the vaccine and biotechnology sectors [1]